NO20063871L - Fremgangsmaer for indusering av autolyse i infeksiose bakteria - Google Patents

Fremgangsmaer for indusering av autolyse i infeksiose bakteria

Info

Publication number
NO20063871L
NO20063871L NO20063871A NO20063871A NO20063871L NO 20063871 L NO20063871 L NO 20063871L NO 20063871 A NO20063871 A NO 20063871A NO 20063871 A NO20063871 A NO 20063871A NO 20063871 L NO20063871 L NO 20063871L
Authority
NO
Norway
Prior art keywords
infection
treatment
bacteria
infectious bacteria
autolysis
Prior art date
Application number
NO20063871A
Other languages
English (en)
Inventor
Keith Alan Charlton
Andrew Justin Radcliff Porter
Ian Broadbent
Original Assignee
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd filed Critical Haptogen Ltd
Publication of NO20063871L publication Critical patent/NO20063871L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Foreliggende oppfinnelse angår fremgangsmåter for avliving av infeksiøse bakterier ved modulering av den ekstra-cellulære konsentrasjonen av bakteriecelle signaliseringsmolekyler. Dette har den effekt at det induserer hurtig celledød (autolyse) i majoriteten av bakterielle celler, og forhindrer virulens eller gjenvinning av en benign tilstand i overlevende celler. Disse reseptorene har anvendelse for behandling av individer som er mottakelige for infeksjon, behandling av pasienter med eksisterende infeksjoner, i sykdomshåndtering, og i relaterte anvendelse hvor verten for infeksjon er et dyr eller plante. Sammensetningene beskrevet heri er spesielt relevante for Pseudomonas aeruginosa infeksjon, for eksempel i behandling av pulmonar infeksjon i cystisk fibrose pasienter, og representerer en unik bakteriell medisinering som ikke direkte målsøker bakteriene.
NO20063871A 2004-03-27 2006-08-30 Fremgangsmaer for indusering av autolyse i infeksiose bakteria NO20063871L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0407008.2A GB0407008D0 (en) 2004-03-27 2004-03-27 Methods for inducing rapid cell death (autolysis) in infectious bacteria
PCT/GB2005/001108 WO2005094883A2 (en) 2004-03-27 2005-03-24 Methods for inducing autolysis in infectious bacteria

Publications (1)

Publication Number Publication Date
NO20063871L true NO20063871L (no) 2006-08-30

Family

ID=32188889

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063871A NO20063871L (no) 2004-03-27 2006-08-30 Fremgangsmaer for indusering av autolyse i infeksiose bakteria

Country Status (15)

Country Link
US (3) US20070218058A1 (no)
EP (2) EP2261260A3 (no)
JP (2) JP5167466B2 (no)
KR (2) KR20070050865A (no)
CN (1) CN1934134B (no)
AT (1) ATE548390T1 (no)
AU (1) AU2005227666B2 (no)
CA (1) CA2558435A1 (no)
DK (1) DK1730197T3 (no)
ES (1) ES2381374T3 (no)
GB (1) GB0407008D0 (no)
HK (1) HK1099316A1 (no)
NO (1) NO20063871L (no)
SG (1) SG151316A1 (no)
WO (1) WO2005094883A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528935B1 (en) * 2002-08-13 2012-03-21 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
JP5170403B2 (ja) * 2008-03-14 2013-03-27 国立大学法人 筑波大学 細菌の増殖を制御する化合物及びその応用
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
US10472326B2 (en) * 2014-04-03 2019-11-12 Helmholtz-Zentrum für Infektionsforschung GmbH PQSR modulators
CN108513984B (zh) * 2018-04-14 2020-12-29 华南农业大学 Ahl分子作为化学农药杀菌增效剂在黄单胞杆菌引起的黑腐病防治中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
AU3580800A (en) 1998-11-25 2000-06-26 Mcw Research Foundation, Inc. Method of and compositions for immunization with the (pseudomonas) v antigen
GB9924195D0 (en) 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0007588D0 (en) 2000-03-30 2000-05-17 Univ Nottingham N-Acyl homoserine lactones
US6703513B1 (en) * 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
EP1528935B1 (en) * 2002-08-13 2012-03-21 Haptogen Ltd Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria

Also Published As

Publication number Publication date
EP2261260A2 (en) 2010-12-15
AU2005227666B2 (en) 2011-09-01
ATE548390T1 (de) 2012-03-15
US20110027280A1 (en) 2011-02-03
EP1730197B1 (en) 2012-03-07
AU2005227666A1 (en) 2005-10-13
US20130011400A1 (en) 2013-01-10
KR20070050865A (ko) 2007-05-16
HK1099316A1 (en) 2007-08-10
EP2261260A3 (en) 2011-01-05
WO2005094883A2 (en) 2005-10-13
SG151316A1 (en) 2009-04-30
DK1730197T3 (da) 2012-06-25
CN1934134A (zh) 2007-03-21
CN1934134B (zh) 2012-01-11
JP5167466B2 (ja) 2013-03-21
CA2558435A1 (en) 2005-10-13
GB0407008D0 (en) 2004-04-28
KR20130001741A (ko) 2013-01-04
US20070218058A1 (en) 2007-09-20
WO2005094883A3 (en) 2006-01-12
EP1730197A2 (en) 2006-12-13
JP2007530649A (ja) 2007-11-01
JP2013040191A (ja) 2013-02-28
ES2381374T3 (es) 2012-05-25

Similar Documents

Publication Publication Date Title
Minden-Birkenmaier et al. Honey-based templates in wound healing and tissue engineering
Tomb et al. New proof-of-concept in viral inactivation: virucidal efficacy of 405 nm light against feline calicivirus as a model for norovirus decontamination
Davis et al. Effectiveness of a polyhexanide irrigation solution on methicillin‐resistant Staphylococcus aureus biofilms in a porcine wound model
NO20063871L (no) Fremgangsmaer for indusering av autolyse i infeksiose bakteria
Bonamonte et al. Aquarium-borne Mycobacterium marinum skin infection. Report of 15 cases and review of the literature
Arnold et al. Bacterial biofilms and periprosthetic infections
Khokhar et al. Viricidal treatments for prevention of coronavirus infection
Azman et al. Actinobacteria—a promising natural source of anti-biofilm agents
Gupta et al. Inactivation of micro-organisms isolated from infected lower limb arthroplasties using high-intensity narrow-spectrum (HINS) light
Gupta et al. Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichophyton mentagrophytes using an in vitro test system
Argyraki et al. Comparison of UVB and UVC irradiation disinfection efficacies on Pseudomonas Aeruginosa (P. aeruginosa) biofilm
Wang et al. Virucidal effect of povidone-iodine against SARS-CoV-2 in vitro
Lin et al. Application progress of nano silver dressing in the treatment of diabetic foot
Parvin et al. Efficacy of surgical/wound washes against bacteria: Effect of different in vitro models
ATE479430T1 (de) Verwendung von retinoid-typ verbindungen als antibakterielle mittel gegen staphylococcus aureus
Stibich et al. The microbiological impact of pulsed xenon ultraviolet disinfection on resistant bacteria, bacterial spore and fungi and viruses
EP1639971A4 (en) COMPOSITIONS FOR SKIN PROTECTION
Young et al. Recommendations for best disinfectant practices to reduce the spread of infection via wrestling mats
CN103907598A (zh) 一种氯消毒剂泡腾片
CN101491245B (zh) 一种含林蛙抗菌肽的消毒制剂及其制备方法和应用
Trizna et al. Improving the efficacy of antimicrobials against biofilm-embedded bacteria using bovine hyaluronidase azoximer (Longidaza®)
El-Azizi et al. Efficacy of ultraviolet C light at sublethal dose in combination with antistaphylococcal antibiotics to disinfect catheter biofilms of methicillin-susceptible and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis in vitro
Wietzikoski Lovato et al. High frequency equipment promotes antibacterial effects dependent on intensity and exposure time
CN102754666A (zh) 医疗机构物体表面草本消毒剂
Alipour-Khezri et al. Pseudomonas aeruginosa Bacteriophages and Their Clinical Applications